Similar articles for PMID: 32015064

Year	Number of Results
2004	3
2005	1
2008	1
2009	1
2011	1
2012	5
2013	8
2014	2
2015	4
2016	13
2017	24
2018	28
2019	19
2020	28
2021	21
2022	12
2023	6
2024	0

1

Familial hypercholesterolemia: Detect, treat, and ask about family.

Shah NP, Ahmed HM, Wilson Tang WH. Shah NP, et al. Cleve Clin J Med. 2020 Feb;87(2):109-120. doi: 10.3949/ccjm.87a.19021. Cleve Clin J Med. 2020. PMID: 32015064 Free article. Review.

2

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.

Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G. Thedrez A, et al. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):592-598. doi: 10.1161/ATVBAHA.117.310217. Epub 2017 Dec 28. Arterioscler Thromb Vasc Biol. 2018. PMID: 29284604 Free PMC article. Clinical Trial.

3

Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.

Miname MH, Santos RD. Miname MH, et al. Prog Cardiovasc Dis. 2019 Sep-Oct;62(5):414-422. doi: 10.1016/j.pcad.2019.10.003. Epub 2019 Oct 25. Prog Cardiovasc Dis. 2019. PMID: 31669498 Review.

4

Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.

Della Badia LA, Elshourbagy NA, Mousa SA. Della Badia LA, et al. Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29. Pharmacol Ther. 2016. PMID: 27133571 Review.

5

Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).

Gaudet D, Durst R, Lepor N, Bakker-Arkema R, Bisgaier C, Masson L, Golden L, Kastelein JJ, Hegele RA, Stein E. Gaudet D, et al. Am J Cardiol. 2019 Dec 15;124(12):1876-1880. doi: 10.1016/j.amjcard.2019.09.010. Epub 2019 Sep 26. Am J Cardiol. 2019. PMID: 31685212 Clinical Trial.

6

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.

Ortega Martínez de Victoria E. Ortega Martínez de Victoria E. Endocrinol Diabetes Nutr. 2017 Aug-Sep;64(7):341-344. doi: 10.1016/j.endinu.2017.04.005. Epub 2017 Jun 3. Endocrinol Diabetes Nutr. 2017. PMID: 28745604 English, Spanish. No abstract available.

7

Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.

Rubba P, Gentile M, Marotta G, Iannuzzi A, Sodano M, De Simone B, Jossa F, Iannuzzo G, Giacobbe C, Di Taranto MD, Fortunato G. Rubba P, et al. Eur J Prev Cardiol. 2017 Jul;24(10):1051-1059. doi: 10.1177/2047487317702040. Epub 2017 Mar 29. Eur J Prev Cardiol. 2017. PMID: 28353356

8

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL; Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Ridker PM, et al. J Clin Lipidol. 2018 Jul-Aug;12(4):958-965. doi: 10.1016/j.jacl.2018.03.088. Epub 2018 Apr 3. J Clin Lipidol. 2018. PMID: 29685591 Clinical Trial.

9

Severe xanthomatosis in heterozygous familial hypercholesterolemia.

Aljenedil S, Ruel I, Watters K, Genest J. Aljenedil S, et al. J Clin Lipidol. 2018 Jul-Aug;12(4):872-877. doi: 10.1016/j.jacl.2018.03.087. Epub 2018 Apr 3. J Clin Lipidol. 2018. PMID: 29778561

10

A keen eye for risk.

Ford TJ, Rocchiccioli P. Ford TJ, et al. BMJ. 2018 Feb 1;360:j5884. doi: 10.1136/bmj.j5884. BMJ. 2018. PMID: 29419393 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

158 results

Results by year